Fundraising Fox

Amphivena Therapeutics

San Francisco, US · Founded 2012 · Delaware corporation · 4 known investors

Biotech

Founders & leadership

JG
Jeanmarie GuenotNamed on SEC filing
FF
Florian FischerNamed on SEC filing

Board

LELuke Evnin
Luke Evninin𝕏Board directorAdvisor at MPM BioImpact

Investors · 4

+ND CapitalreportedWoodside · $540K – $5.4M
MPM BioImpactreported · 2 sourcesBoston · $1M – $15Mvia Vinay Bhaskar · board
Qiming HealthcarereportedBellevue
Qiming Venture Partners USAreportedCambridge

Reported raises · per SEC filings

Form D private placements

$65.2M disclosed across 3 rounds · 2013–2018

▶$38.7MraisedDec 2018 · 15 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Luke EvninDirector
  • Peter Van VasselaerExecutive Officer, Director
  • Mark McDadeDirector
  • Jeanmarie GuenotExecutive Officer, Director
  • Eric MoessingerDirector
  • Christian RichardDirector
Offering amount
$50M
Amount sold
$38.7M
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedJul 2017 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luke EvninDirector
  • Jeanmarie GuenotExecutive Officer, Director
  • Christian RichardDirector
  • Vinay BhaskarDirector
  • Florian FischerDirector
Offering amount
$7M
Amount sold
$7M
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19.5MraisedJun 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luke EvninDirector
  • Jeanmarie GuenotExecutive Officer, Director
  • Florian FischerDirector
Offering amount
$19.5M
Amount sold
$19.5M
Proceeds to insiders
$100K
First sale
Jul 2013
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

What is Brief History of Amphivena Therapeutics Company? – businessmodelcanvastemplate.combusinessmodelcanvastemplate.com · Dec 2024Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564prnewswire.com · Dec 2020Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio - BioSpacebiospace.com · Sep 2019Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors - MedCity Newsmedcitynews.com · Sep 2019Quiet biotech Amphivena nabs $62M funding round | Fierce Biotechfiercebiotech.com · Sep 2019Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy for the Treatment of Acute Myeloid Leukemia - BioSpacebiospace.com · Nov 2017

Frequently asked questions

Who are Amphivena Therapeutics's investors?
Amphivena Therapeutics's investors include +ND Capital, MPM BioImpact, Qiming Healthcare, Qiming Venture Partners USA.
How much funding has Amphivena Therapeutics raised?
Amphivena Therapeutics has disclosed $65.2M raised across 3 rounds.
Where is Amphivena Therapeutics headquartered?
Amphivena Therapeutics is headquartered in San Francisco, US.